scholarly journals In Vitro Activity of Ceftaroline, Linezolid, and Tigecycline against Staphylococcus aureus and Streptococcus pneumoniae by Infection Site in the Africa/Middle East Region, 2014-17

2020 ◽  
Vol 13 (2) ◽  
pp. 334-335
Author(s):  
I Morrissey ◽  
A Johnson ◽  
M Hackel ◽  
G Stone ◽  
Dowzicky M ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Streptococcus Pneumoniae ◽  
Middle East ◽  
Vitro Activity ◽  
Infection Site ◽  
In Vitro Activity ◽  
East Region ◽  
Middle East Region

scholarly journals Determining Linezolid’s Baseline In Vitro Activity in Canada Using Gram-Positive Clinical Isolates Collected prior to Its National Release

2002 ◽  
Vol 46 (6) ◽  
pp. 1989-1992 ◽  
Author(s):  
James A. Karlowsky ◽  
Laurie J. Kelly ◽  
Ian A. Critchley ◽  
Mark E. Jones ◽  
Clyde Thornsberry ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Streptococcus Pneumoniae ◽  
Staphylococcus Epidermidis ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
Clinical Use ◽  
In Vitro Activity ◽  
Gram Positive ◽  
Future Studies

ABSTRACT All of the isolates of Staphylococcus aureus (n = 317), Enterococcus species (n = 315), Streptococcus pneumoniae (n = 282), and Staphylococcus epidermidis (n = 176) collected at 16 Canadian microbiology laboratories from October 2000 to April 2001 were susceptible to linezolid. Future studies will determine how linezolid clinical use in Canada affects its in vitro activity.

scholarly journals In Vitro Activities of DX-619 and Comparison Quinolones against Gram-Positive Cocci

2006 ◽  
Vol 50 (6) ◽  
pp. 2255-2257 ◽  
Author(s):  
Paul A. Wickman ◽  
Jennifer A. Black ◽  
Ellen Smith Moland ◽  
Kenneth S. Thomson
Keyword(s):  
Staphylococcus Aureus ◽  
Streptococcus Pneumoniae ◽  
Streptococcus Pyogenes ◽  
Vitro Activity ◽  
The Novel ◽  
In Vitro Activity ◽  
Coagulase Negative Staphylococci ◽  
Gram Positive ◽  
Gram Positive Cocci

ABSTRACT The in vitro activity of the novel quinolone DX-619 was compared to those of currently available quinolones against U.S. clinical isolates of Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus spp., Streptococcus pyogenes, and Streptococcus pneumoniae. DX-619 was the most potent quinolone overall, indicating possible utility as an anti-gram-positive quinolone.

scholarly journals In Vitro Activity of Nafithromycin (WCK 4873) against Chlamydia pneumoniae

2021 ◽  
Author(s):  
Stephan Kohlhoff ◽  
Margaret R. Hammerschlag
Keyword(s):  
Staphylococcus Aureus ◽  
Streptococcus Pneumoniae ◽  
Moraxella Catarrhalis ◽  
Chlamydia Pneumoniae ◽  
Community Acquired Pneumonia ◽  
Clinical Development ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Hemophilus Influenzae

Nafithromycin (13 WCK 4873) is a novel lactone ketolide under clinical development as an orally administrated antibiotic for treatment of community acquired pneumonia (CAP) caused by Streptococcus pneumoniae, Hemophilus influenzae, Moraxella catarrhalis , and methicillin susceptible Staphylococcus aureus .…

Sign in / Sign up

Export Citation Format

Share Document